Journal Home
Search for

Volume 13, Issue 12, Pages 1487-1498 (December 2007)


View previous. 15 of 21 View next.

Higher Risk of Cytomegalovirus and Aspergillus Infections in Recipients of T Cell–Depleted Unrelated Bone Marrow: Analysis of Infectious Complications in Patients Treated with T Cell Depletion Versus Immunosuppressive Therapy to Prevent Graft-versus-Host Disease

Jo-Anne H. van BurikaCorresponding Author Informationemail address, Shelly L. Carterb, Alison G. Freifeldc, Kevin P. Highd, Kamar T. Goddere, Genovefa A. Papanicolaouf, Adam M. Mendizabalb, John E. Wagnera, Saul Yanovichg, Nancy A. Kernanf

Received 17 July 2007; accepted 30 August 2007.

Abstract 

Serious infections are a major obstacle limiting the usefulness of unrelated donor marrow transplantation. Graft-versus-host disease (GVHD) and its therapy are associated with a high risk of opportunistic infection. In this study, patients were randomized to receive 1 of 2 GVHD prophylaxis strategies, marrow T cell depletion, and cyclosporine (TCD) or methotrexate/cyclosporine (M/C) after transplantation. The patients underwent transplantation between March 1995 and October 2000 as part of a multicenter randomized trial. As a secondary analysis, we analyzed infections in this study cohort. Among the 404 patients who underwent transplantation, a total of 1598 infections were reported. The rates of serious and fatal infections did not differ between the TCD and M/C groups. Bacterial infections accounted for 1/3 of serious infections in each treatment arm. A significantly higher incidence of severe cytomegalovirus (CMV) and life-threatening or fatal aspergillus infections was observed in the patients receiving TCD (CMV, 28% vs 17% [P = .02]; aspergillosis, 16% vs 7% [P < .01]). The only independent risk factor for serious infection was the development of grade III-IV acute GVHD (aGVHD; hazard ratio = 1.41; 95% confidence interval = 1.03-1.91). Strategies to speed immune recovery, even in the absence of GVHD, are needed to overcome the risk of infection after unrelated donor transplantation.

a Departments of Pediatrics and Medicine, University of Minnesota, Minneapolis, Minnesota

b The EMMES Corporation, Rockville, Maryland

c Department of Medicine, University of Nebraska, Omaha, Nebraska

d Department of Medicine, Wake Forest University, Winston-Salem, North Carolina

e Department of Pediatrics, Virginia Commonwealth University, Richmond, Virginia

f Departments of Medicine and Pediatrics, Memorial-Sloan Kettering Cancer Center, New York, New York

g Department of Medicine, Medical College of Virginia, Richmond, Virginia

Corresponding Author InformationCorrespondence and reprint requests: Jo-Anne van Burik, MMC 250, 420 Delaware Street SE, Minneapolis, MN, 55455; Tel: 612- 625-8462; Fax: 612-625-4410.

PII: S1083-8791(07)00440-5

doi:10.1016/j.bbmt.2007.08.049


View previous. 15 of 21 View next.